Loading
A phase 2 trial of Trastuzumab deruxtecan in melanoma, run by AstraZeneca, active and no longer recruiting.
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations is a phase 2 interventional study registered as NCT04639219 by AstraZeneca, with 102 participants enrolled, started 2020-12-30 and due to reach its primary completion in 2023-01-25. Interventions recorded: Trastuzumab deruxtecan. Conditions listed: Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast. Results were posted on ClinicalTrials.gov in 2024; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
102 enrolled.
95% CI 20.8 to 39.3; Figures from the ClinicalTrials.gov results section (first posted 2024-02-15), not from a publication
Source95% CI 8.3 to 14.9; Figures from the ClinicalTrials.gov results section (first posted 2024-02-15), not from a publication
SourceShares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC).
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC).
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC).
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC).
Shares Trastuzumab deruxtecan, Topoisomerase-I inhibitors (and ADC payloads), AstraZeneca, Antibody-drug conjugate (ADC).